Purple Biotech Ltd (TA:KTOV) — Market Cap & Net Worth
Market Cap & Net Worth: Purple Biotech Ltd (KTOV)
Purple Biotech Ltd (TA:KTOV) has a market capitalization of $461.41K (ILA172.11 Million) as of September 16, 2026. Listed on the TA stock exchange, this Israel-based company holds position #31086 globally and #458 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Purple Biotech Ltd's stock price ILA1.00 by its total outstanding shares 172106000 (172.11 Million). Also see KTOV total asset value for a full breakdown of the balance sheet.
Purple Biotech Ltd Market Cap History: 2015 to 2026
Purple Biotech Ltd's market capitalization history from 2015 to 2026. Data shows change from $562.92 Million to $461.41K (-53.20% CAGR). Also see Purple Biotech Ltd (KTOV) cash flow conversion for how efficiently the company converts equity into cash flow.
Purple Biotech Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Purple Biotech Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Purple Biotech Ltd (KTOV) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
118.12x
Purple Biotech Ltd's market cap is 118.12 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $365.44 Million | $100.00K | -$12.27 Million | 3654.37x | N/A |
| 2018 | $121.81 Million | $1.00 Million | -$5.20 Million | 121.81x | N/A |
| 2019 | $118.12 Million | $1.00 Million | -$5.85 Million | 118.12x | N/A |
Competitor Companies of KTOV by Market Capitalization
Companies near Purple Biotech Ltd in the global market cap rankings as of September 16, 2026. Review Purple Biotech Ltd tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Purple Biotech Ltd by market ranking:
- Peptron Inc (KQ:087010): Ranked #7067 globally with a market cap of $1.57 Billion USD ( ₩2.31 Trillion KRW).
- Bioneer Corporation (KQ:064550): Ranked #17802 globally with a market cap of $147.65 Million USD ( ₩217.88 Billion KRW).
- MEDIPOST Co. Ltd (KQ:078160): Ranked #19636 globally with a market cap of $90.68 Million USD ( ₩133.80 Billion KRW).
- Cell Biotech Co. Ltd (KQ:049960): Ranked #20066 globally with a market cap of $81.77 Million USD ( ₩120.66 Billion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #7067 | Peptron Inc | KQ:087010 | $1.57 Billion | ₩150800.00 |
| #17802 | Bioneer Corporation | KQ:064550 | $147.65 Million | ₩9860.00 |
| #19636 | MEDIPOST Co. Ltd | KQ:078160 | $90.68 Million | ₩8700.00 |
| #20066 | Cell Biotech Co. Ltd | KQ:049960 | $81.77 Million | ₩15630.00 |
Purple Biotech Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Purple Biotech Ltd's market cap moved from $562.92 Million to $ 461.41K, with a yearly change of -53.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA461.41K | -9.09% |
| 2025 | ILA507.55K | -86.25% |
| 2024 | ILA3.69 Million | -74.92% |
| 2023 | ILA14.72 Million | -38.06% |
| 2022 | ILA23.76 Million | -57.08% |
| 2021 | ILA55.37 Million | -4.23% |
| 2020 | ILA57.81 Million | -51.05% |
| 2019 | ILA118.12 Million | -3.03% |
| 2018 | ILA121.81 Million | -66.67% |
| 2017 | ILA365.44 Million | -32.99% |
| 2016 | ILA545.39 Million | -3.11% |
| 2015 | ILA562.92 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Purple Biotech Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $461.41K USD |
| MoneyControl | $461.41K USD |
| MarketWatch | $461.41K USD |
| marketcap.company | $461.41K USD |
| Reuters | $461.41K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Purple Biotech Ltd
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension i… Read more